Logo image of CCCC

C4 THERAPEUTICS INC (CCCC) Stock Fundamental Analysis

NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock - Currency: USD

1.25  +0.15 (+13.64%)

After market: 1.24 -0.01 (-0.8%)

Fundamental Rating

4

Taking everything into account, CCCC scores 4 out of 10 in our fundamental rating. CCCC was compared to 568 industry peers in the Biotechnology industry. While CCCC has a great health rating, there are worries on its profitability. CCCC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CCCC had negative earnings in the past year.
In the past year CCCC has reported a negative cash flow from operations.
In the past 5 years CCCC always reported negative net income.
CCCC had a negative operating cash flow in each of the past 5 years.
CCCC Yearly Net Income VS EBIT VS OCF VS FCFCCCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.12%, CCCC is in the better half of the industry, outperforming 67.25% of the companies in the same industry.
With a decent Return On Equity value of -48.76%, CCCC is doing good in the industry, outperforming 65.67% of the companies in the same industry.
Industry RankSector Rank
ROA -30.12%
ROE -48.76%
ROIC N/A
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
CCCC Yearly ROA, ROE, ROICCCCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCCC Yearly Profit, Operating, Gross MarginsCCCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CCCC has more shares outstanding
CCCC has more shares outstanding than it did 5 years ago.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCCC Yearly Shares OutstandingCCCC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CCCC Yearly Total Debt VS Total AssetsCCCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CCCC has an Altman-Z score of -2.41. This is a bad value and indicates that CCCC is not financially healthy and even has some risk of bankruptcy.
CCCC has a Altman-Z score (-2.41) which is comparable to the rest of the industry.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.41
ROIC/WACCN/A
WACC10.33%
CCCC Yearly LT Debt VS Equity VS FCFCCCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.71 indicates that CCCC has no problem at all paying its short term obligations.
CCCC has a better Current ratio (5.71) than 61.62% of its industry peers.
CCCC has a Quick Ratio of 5.71. This indicates that CCCC is financially healthy and has no problem in meeting its short term obligations.
CCCC has a better Quick ratio (5.71) than 62.15% of its industry peers.
Industry RankSector Rank
Current Ratio 5.71
Quick Ratio 5.71
CCCC Yearly Current Assets VS Current LiabilitesCCCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.23% over the past year.
CCCC shows a strong growth in Revenue. In the last year, the Revenue has grown by 71.46%.
The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)43.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)71.46%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%58.75%

3.2 Future

CCCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 76.25% yearly.
The Revenue is expected to grow by 124.94% on average over the next years. This is a very strong growth
EPS Next Y-27.53%
EPS Next 2Y-6.91%
EPS Next 3Y-3.26%
EPS Next 5Y76.25%
Revenue Next Year-32.33%
Revenue Next 2Y-3.95%
Revenue Next 3Y-18.33%
Revenue Next 5Y124.94%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CCCC Yearly Revenue VS EstimatesCCCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
CCCC Yearly EPS VS EstimatesCCCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 40 60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
Also next year CCCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCCC Price Earnings VS Forward Price EarningsCCCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CCCC Per share dataCCCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CCCC's earnings are expected to decrease with -3.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.91%
EPS Next 3Y-3.26%

More info and screens

0

5. Dividend

5.1 Amount

CCCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

C4 THERAPEUTICS INC

NASDAQ:CCCC (4/17/2025, 8:06:19 PM)

After market: 1.24 -0.01 (-0.8%)

1.25

+0.15 (+13.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-08 2025-05-08
Inst Owners85.76%
Inst Owner Change0%
Ins Owners2.59%
Ins Owner Change31.32%
Market Cap88.74M
Analysts78.75
Price Target15.87 (1169.6%)
Short Float %14.77%
Short Ratio5.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.58%
Min EPS beat(2)-0.55%
Max EPS beat(2)9.7%
EPS beat(4)2
Avg EPS beat(4)6.55%
Min EPS beat(4)-14.38%
Max EPS beat(4)31.42%
EPS beat(8)4
Avg EPS beat(8)6.37%
EPS beat(12)6
Avg EPS beat(12)5.42%
EPS beat(16)10
Avg EPS beat(16)10.46%
Revenue beat(2)1
Avg Revenue beat(2)113.22%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)227.41%
Revenue beat(4)2
Avg Revenue beat(4)77.32%
Min Revenue beat(4)-63.22%
Max Revenue beat(4)227.41%
Revenue beat(8)4
Avg Revenue beat(8)39.55%
Revenue beat(12)5
Avg Revenue beat(12)24.65%
Revenue beat(16)9
Avg Revenue beat(16)39.44%
PT rev (1m)-0.4%
PT rev (3m)-3.6%
EPS NQ rev (1m)3.57%
EPS NQ rev (3m)5.26%
EPS NY rev (1m)-2.18%
EPS NY rev (3m)-9.04%
Revenue NQ rev (1m)16.65%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)12.5%
Revenue NY rev (3m)45.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.49
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.5
BVpS3.04
TBVpS3.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.12%
ROE -48.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.9%
Cap/Sales 0.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.71
Quick Ratio 5.71
Altman-Z -2.41
F-Score5
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)142.71%
Cap/Depr(5y)110.83%
Cap/Sales(3y)8.81%
Cap/Sales(5y)6.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y-27.53%
EPS Next 2Y-6.91%
EPS Next 3Y-3.26%
EPS Next 5Y76.25%
Revenue 1Y (TTM)71.46%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%58.75%
Revenue Next Year-32.33%
Revenue Next 2Y-3.95%
Revenue Next 3Y-18.33%
Revenue Next 5Y124.94%
EBIT growth 1Y15.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.98%
EBIT Next 3Y-17.34%
EBIT Next 5YN/A
FCF growth 1Y39.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.01%
OCF growth 3YN/A
OCF growth 5YN/A